Momentum

Relative Strength (%)
1m-22.62%
3m
6m
1yr
Volume Change (%)
10d/3m
Price vs... (%)
52w High-55.04%
50d MA
200d MA

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Latest News & Insights for MGNX

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202131st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2021 / 2022

Blurred out image of MacroGenics EPS forecast chart

Profile Summary

MacroGenics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. The Company's lead product, MARGENZA, is a HER2/neu receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. In addition, the Company has a pipeline of product candidates in human clinical testing, including eight immuno-oncology programs, such as Flotetuzumab (CD123 x CD3), Retifanlimab (PD-1), Enoblituzumab (anti-B7-H3), Tebotelimab (PD-1 x LAG-3), MGD019 (PD-1 x CTLA-4), MGC018 (B7-H3), IMGC936 (ADAM9) and MGD014 (HIV x CD3). These pipelines are created primarily using its antibody-based technology platforms.

Directors

Last Annual
December 31st, 2020
Last Interim
September 30th, 2021
Incorporated
August 14th, 2000
Public Since
October 10th, 2013
No. of Shareholders
63
No. of Employees
370
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Select Market
Shares in Issue
61,258,001

MGNX Share Price Performance

Latest News for MGNX

Upcoming Events for MGNX

MacroGenics Inc at JMP Group Hematology and Oncology Summit (Virtual)

Q4 2021 MacroGenics Inc Earnings Release

Q1 2022 MacroGenics Inc Earnings Release

MacroGenics Inc Annual Shareholders Meeting

Similar to MGNX

2Seventy Bio

us flag iconNASDAQ Global Select Market

Picture of 4D Molecular Therapeutics logo

4D Molecular Therapeutics

us flag iconNASDAQ Global Select Market

Picture of AbCellera Biologics logo

AbCellera Biologics

us flag iconNASDAQ Global Select Market

AbSci

us flag iconNASDAQ Global Select Market

Picture of ACADIA Pharmaceuticals logo

ACADIA Pharmaceuticals

us flag iconNASDAQ Global Select Market

FAQ

Or unlock with your email

Or unlock with your email